On a mission to simplify cell therapy manufacturing and bring life-saving treatments closer to patients.

For years, the promise of personalized cell therapy has been overshadowed by one critical hurdle, manufacturing. The process, often manual and resource-intensive, makes it difficult to scale treatments efficiently. Patients in urgent need are left waiting, and companies face rising costs with limited capacity. The industry needed more than innovation in treatment, it needed transformation in how these therapies are made.

Adva Biotechnology Ltd, under the leadership of Dr. Ohad Karnieli, has taken on this challenge with a clear vision. With years of experience in the field of cell and gene therapy, he understood that solving the manufacturing issue was just as important as developing the therapy itself.

Adva’s solution is the ADVA X3, an advanced, all-in-one system designed to make the manufacturing process simpler, faster, and more reliable. This closed and automated platform can carry out complex steps without the need for large cleanrooms or constant manual handling. It uses real-time monitoring and intelligent technology to ensure quality at every stage. It is also flexible enough to be used in different locations, bringing treatment closer to the patient.

Dr. Ohad’s goal with Adva is to remove the barriers that slow down progress in personalized medicine. By improving how treatments are made, Adva is helping more patients receive care on time. The company is creating a future where innovation in therapy is matched by innovation in how it is delivered.

Making Cell Therapy Scalable, Affordable and Easy to Use

Adva’s ADVA X3 platform offers a practical solution to some of the most difficult challenges in cell therapy manufacturing, high costs, limited scalability, and labor-heavy processes. This system is more than an automation tool; it represents a shift in how therapies can be produced at scale, closer to the point of care.

The platform runs on CAMP technology, which uses AI and machine learning to manage 14 critical parameters. This allows for real-time monitoring and predictive adjustments, helping ensure each batch remains consistent and high in quality.

It is designed to be flexible. The ADVA X3 supports a wide range of therapies, including CAR T, TCR, NK, TIL, exosomes, and viral vectors. Its modular structure and programmable units make it adaptable to various protocols and clinical workflows.

Ease of use is another key feature. The platform is built so that trained technicians can operate it. It comes with plug-and-play installation, aseptic connectors that do not require welding, automated system checks, and a user-friendly interface. This shortens the setup time and simplifies tech transfers between sites.

In terms of cost, the platform helps reduce overall production expenses by up to 80 percent. It operates with a closed, single-use system in low-grade cleanrooms, which significantly lowers infrastructure and operational costs.

By combining intelligent control, flexibility, ease of use, and cost-efficiency, ADVA X3 is helping set a new standard in decentralized cell therapy manufacturing, making high-quality treatments more accessible and scalable.

CAMP Enables Real-Time Personalization in Cell Therapy

What powers the flexibility and performance of the ADVA X3 platform is its built-in CAMP® (Continuous Adaptive Multi-Parameter) technology. This intelligent control system is what enables the platform to go beyond simple automation and actively respond to changing conditions during manufacturing. While the ADVA X3 solves the challenges of cost, scale, and usability, CAMP ensures that the therapies produced are precisely tailored and consistent, batch after batch, patient after patient.

CAMP works by mimicking the body’s ability to keep internal conditions in balance. It monitors and adjusts 14 critical parameters in real time to create an optimal environment for cell growth. This responsiveness supports strong expansion and high-quality output across a wide range of therapies.

This becomes especially important for autologous treatments, where each patient’s cells behave differently. Variability in these cases can often lead to poor yields or inconsistent results. CAMP solves this by adapting the manufacturing process to the individual characteristics of each donor’s cells, reducing manual intervention and ensuring better reliability.

By aligning with the ADVA X3’s goal of making cell therapy easier to scale and standardize, CAMP technology plays a central role. It brings precision to flexibility and consistency to personalization, making advanced therapies easier to produce, not just in labs but in clinics, closer to where patients are treated.

 

Real-Time Monitoring Simplifies CAR-T Scale-Up

With CAMP technology making precision and personalization possible at scale, the next logical step was to extend this control to more complex therapies like CAR-T. These therapies involve highly sensitive, patient-specific cells that react quickly to even the smallest environmental shifts. Scaling them up for GMP manufacturing has always been a challenge, especially when moving from research labs to clinical production.

The ADVA X3, with its integrated CAMP system, made that transition smoother. Its ability to track and respond to 14 parameters in real time gave manufacturers something they never had before: continuous visibility into cell behavior throughout the process. This insight proved critical. It allowed for fine-tuning on the fly without compromising cell quality or yield.

Before this, scaling CAR-T involved guesswork. Adjustments carried real risk because there was no window into what the cells were experiencing. CAMP changed that by offering real-time metabolic feedback, allowing operators to steer the process with clarity and control.

As one customer summed it up, “For the first time, I felt like I was driving with my eyes open.”

One Platform for Multiple Cell Therapies

The Adva X3 platform has been designed to support the manufacturing of various therapies like CAR-T, TCR, NK, TILs, exosomes, and viruses using a single system. Its flexible structure allows most unit operations to be carried out within one platform.

The system’s open architecture makes it possible for users to create and adjust their own protocols, including workflow design, reagent selection, and volume settings. For some specific therapies, a tailored single-use kit may be required, but the main device stays the same. This ensures stable performance across different therapy types.

Making Decentralized Manufacturing cGMP-Compliant

One of the biggest regulatory challenges in decentralized manufacturing is meeting strict current Good Manufacturing Practice (cGMP) standards. Adva Biotechnology addresses this through its Adva X3 system. This fully automated and closed platform includes validated data logging and a simple interface that needs very little user involvement once the process is set up.

The system continuously monitors and controls the process, around the clock, and automatically generates GMP-compliant reports. This helps make regulatory compliance more consistent and dependable.

In addition, the platform supports remote access and control, allowing experts to step in when needed. It also makes it easier to transfer technology and ensures that manufacturing processes remain consistent across different locations. These features are essential for successfully implementing decentralized manufacturing models while maintaining patient safety and regulatory standards.

AI Precision in ADVA X3 Improves Cell Therapy at Every Step

The ADVA X3 platform uses artificial intelligence to monitor and control 14 critical parameters during the cell therapy manufacturing process. This happens in real time and includes continuous adjustments to conditions such as pH, temperature, and flow, all based on how the cells are responding. The system adapts on its own, maintaining consistent quality without needing manual intervention.

For manufacturers, this level of control leads to several important advantages. There is a noticeable improvement in batch success rates, which reduces both waste and cost. The process demands less hands-on labor, and the time needed to transfer new technologies into production becomes shorter and more predictable. Data is logged and validated automatically, supporting full regulatory compliance without adding extra layers of manual checks.

For patients, the benefits are equally clear. Therapies become safer and more consistent because the quality of each batch stays the same. Treatment becomes available faster, and optimized cell growth improves how effective the therapy can be. Since the process runs more efficiently, the overall cost of treatment can come down while access increases.

The ADVA X3 brings together intelligent automation and medical-grade precision, creating a system that serves both the demands of modern manufacturing and the needs of patients waiting for advanced therapies.

 

Simplifying Integration Across Diverse Clinical

Adva Biotechnology ensures smooth integration of its platform by combining scientific partnership with tailored implementation. The company begins by assigning a lead scientist to each potential client. This expert takes time to understand the client’s workflow, supports them throughout the setup, and stays involved afterward to provide technical guidance and training. The focus is on long-term support, and this service is offered without additional cost.

Before any purchase is made, Adva conducts a personalized demonstration and evaluation to help clients assess whether the ADVA X3 meets their exact needs. If the system is not a suitable match, the company does not proceed with the sale. This approach reflects Adva’s commitment to lasting value over short-term business gains.

The ADVA X3 platform is built with open architecture, allowing easy integration with existing systems like Manufacturing Execution Systems (MES), quality control tools, and electronic batch records (eBRs). This ensures compatibility with a wide range of clinical and manufacturing environments, even in geographically diverse and technically varied settings.

 

Adapting to Shifts in Science, Technology, and Regulation in Cell Therapy

The team follows a focused approach that combines innovation, flexibility, and a strong dedication to improving patient outcomes. They encourage a mindset that welcomes challenges and values collaboration and future planning. Regular engagement with regulatory bodies helps them stay informed about upcoming requirements and maintain systems that match top global standards.

Alongside this, their research and development team brings together experts from various fields who consistently integrate new technologies into the ADVA X3 platform. This approach allows the team to stay competitive and relevant as both the industry and patient expectations continue to evolve.

 

Commercial Value of ADVA X3 for CDMOs and Hospitals

The ADVA X3 helps customers see a clear return on investment by lowering production costs, improving throughput, and reducing risks tied to labor and compliance. It also speeds up the time it takes to bring products to market.

For both clinical and commercial manufacturing, the system offers scalable, high-quality output at a lower cost with more flexibility. The cost savings per production run reach tens of thousands, which makes the financial benefits both immediate and easy to measure.

 

Advancing Safer Cell Therapies with Data and AI

Adva Biotechnology is focused on advancing life-saving therapies through the continued development of its ADVA X3 platform. The company is working on building a comprehensive data system that connects process parameters, metabolic activity, cellular characteristics, and patient outcomes.

By using the real-time monitoring and AI-driven control features of the X3 platform, along with its ability to generate and analyze large volumes of data, Adva aims to improve both the quality and effectiveness of its therapies. These efforts are expected to support the creation of safer and more reliable treatments for patients.